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summary
Objective: To investigate patients’ motivations for participat-
ing in cardiovascular clinical trials. 
Methods: Patients attending TREAD Research, located within 
Tygerberg Hospital, Parow, Western Cape, between January 
2005 and May 2006 were approached to participate in the 
study. Consenting patients were given a validated question-
naire to complete in their home language. All questionnaires 
were anonymous and 250 consecutive patients completed the 
questionnaire. They provided basic demographic data and 
rated their response to 18 statements concerning factors that 
may or may not have influenced their decision to participate 
in a clinical trial. 
Results: The mean (± SD) age of subjects was 56.3 ± 10.9 
years. A large percentage of the respondents were unem-
ployed (66.5%). Access to medical care was a motivation 
for the majority of patients (90.5%). Ninety-six per cent 
of patients appreciated the regular follow up they received 
as trial participants; 90% of patients entered the trial to 
receive medication, which they could otherwise not afford. 
A substantial 98% of patients participated to learn more 
about their disease. Almost all (99%) wanted to further the 
scientific understanding of their condition. A reassuring 94% 
of subjects felt that they were not pressurised into the study; 
80% of patients disagreed that participation in clinical trials 
was an easy way to obtain money. 
Conclusions: Access to medical care and making a contribu-
tion to scientific knowledge are two of the most common 
motivations for participation in cardiovascular clinical trials. 
The role of remuneration is relatively unimportant. 
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The international drug development industry is under constant 
pressure to reduce the cost and duration of clinical trials. 
Countries such as South Africa, South America and India are 
becoming attractive options for sponsors.1 The South African 
advantage lies in its ability and reputation to produce high-
quality data at 20 to 30% less than the cost in the United States.1 
In addition, the disparate socio-economic conditions found in 
this country result in access to patients with diseases of both the 
industrialised and developing worlds.1
This growing trend to conduct clinical research in developing 
nations has led to a concern regarding the apparent exploita-
tion of vulnerable subjects by international sponsor companies. 
Subjects who may be considered vulnerable are those individu-
als more likely to be unduly influenced in their decision-making 
process, for example regarding matters of healthcare.2 These 
could be participants whose economic status may make them 
more susceptible to financial incentives.2
Little, if any, attention has been paid to the actual motivations 
behind subjects participating in clinical trials in South Africa. 
Understanding the reasons behind patients enrolling in clinical 
trials will assist in the development of patient recruitment strate-
gies and improve retention of subjects. The aim of this study 
was to explore why patients enrol in clinical trials, specifically 
trials investigating atherosclerosis and other chronic diseases of 
lifestyle.
methods
This study was conducted by TREAD Research, a private clini-
cal trial research unit located within Tygerberg Hospital, Parow, 
Western Cape. This unit focuses on trials investigating chronic 
diseases of lifestyle and is affiliated to the Cardiology Unit of 
Stellenbosch University. 
Patients attending the research unit between January 2005 and 
May 2006 were approached to participate in the study. Subjects 
were given an informed consent form to read and sign if they 
wished to participate. The study was approved by the Committee 
for Clinical Trials, Stellenbosch University. Consenting patients 
were given a validated questionnaire to complete in their home 
language. All questionnaires were anonymous and patients were 
instructed to place their completed questionnaire in a sealed 
box in the research unit’s waiting room. Patients were assigned 
a random consecutive number and no identifying data were 
recorded on the questionnaire. 
A total of 250 consecutive patients approached over this 
time period completed the questionnaire. Patients were asked to 
provide basic demographic data, which included their gender, age, 
home language, current occupation and monthly earnings. They 
were then asked to rate their response to 18 statements concern-
ing factors that may or may not have influenced their decision 
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to participate in a clinical trial. Patients were able to choose 
between ‘strongly agree’, ‘agree’, ‘partly agree’ or ‘disagree’. 
Statistical analysis
All questionnaires were examined for missing information. Any 
questions that had not been answered were not included in the final 
analysis. Data were entered into a spreadsheet by an independent 
data capturer. All data were analysed using Statistica Software 
Version 7.0 (StatSoft©, Inc, USA) on a personal computer. 
Parametric data are presented as mean ± standard deviation (SD). 
The monthly income data are expressed as the median (lower and 
upper quartiles). Categorical data are presented as percentages 
of the total number of respondents for that particular question. 
results
The mean (± SD) age of subjects was 56.3 ± 10.9 years. The 
majority of the respondents were Afrikaans speaking (71.7% vs 
27.9% English). There were 118 male subjects (47.0%) and 132 
female subjects (52.6%). Only 4.4% of the respondents were 
not currently participating in a clinical trial. A large percentage 
of the respondents were unemployed (66.5%), with only 31.5% 
registering a paying job or business. The median (lower and 
upper quartile) monthly family income was R1 800.00 (R740.00 
and R5 200). All respondents (100%) indicated they had given 
voluntary informed consent to participate in a clinical trial prior 
to any procedures being performed.
The subjects’ responses to the 18 statements regarding factors 
influencing their decision to participate in a clinical trial are 
presented below in Figs 1–4. Subjects could choose to ‘strongly 
agree’, ‘agree’, ‘partly agree’ or ‘disagree’ with any particular 
statement. The responses are presented in groups, according to 
statement themes, for ease of reference. 
Fig. 1 presents the responses to statements concerning access 
to heath services that the subject could otherwise not afford. Fig. 
2 presents the responses to statements regarding the emotions 
and social motivations concerned with participating in a clinical 
trial. Fig. 3 presents the motivations for contributing to scientific 
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Fig. 1. responses by subjects to statements concerning 
access to services that they could otherwise not afford (n 
= 250), presented as a percentage of the total respondents. 
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Fig. 2. responses to statements by participants regard-
ing the emotions and social motivations associated with 
participating in a clinical trial (n = 250), presented as a 
percentage of the total respondents.
Pe
rc
en
ta
ge
 (%
)
100
80
60
40
20
0
sense of 
belonging
Comfort 
of  
facilities
social 
outing
i have  
the time
i trust the 
institution 
and staff
Partly agree
agree
strongly agree
disagree
Fig. 3. responses to statements concerning contribution 
to scientific study and learning more about their condi-
tion (n = 250), presented as a percentage of the total 
respondents.
Pe
rc
en
ta
ge
 (%
)
100
80
60
40
20
0
learn  
about my 
condition
Contribute 
scientific 
knowledge
i have  
nothing to 
lose
not partici-
pating is 
threat to my 
health
Partly agree
agree
strongly agree
disagree
Fig. 4. responses to statements dealing with the influ-
ence of other people and external loci on the subjects’ 
decision to participate in a clinical trial (n = 250), 
presented as a percentage of the total respondents.
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study and further understanding their condition. Finally, Fig. 4 
presents responses to statements regarding the influence of other 
people and external loci (including money) to the subjects’ deci-
sion to participate in a clinical trial.
discussion
Access to quality medical care and medication is a human right 
but often due to the pressure on government healthcare sector 
resources, many state patients are forced to wait in lengthy 
queues or receive sub-optimal treatment. As trial subjects, 
patients have access to high-quality medical care, including often 
expensive investigations, that they could otherwise not afford. 
Access to these services was a motivation for the majority of 
patients (Fig. 1). 
Regular follow up forms part of most clinical trial protocols, 
whereas the experience in state healthcare facilities is somewhat 
different. It is not therefore surprising that 96% of the patients 
appreciated the regular follow up they received as trial partici-
pants. Access to healthcare and regular follow up was also cited 
by British diabetes trial patients as a motivation for participa-
tion in clinical trials, emphasising that this is not a motivation 
reserved solely for vulnerable populations.3
Access to medication, despite the possibilities of receiving 
a placebo or the existence of unknown side effects, was identi-
fied as a contributory factor to patient involvement in clinical 
research (Fig. 1). It is not a rare occurrence for patients to be 
testing drugs that are not yet available on the South African 
pharmaceutical market but are marketed in North American or 
Western Europe. Despite the possible risks, 90% of the patients 
reported that they enter into trials to receive medication that they 
could otherwise not afford. 
There appear to be emotional and social motivations for 
participating in clinical research. This is supported by the large 
percentage of patients who agreed that they felt a sense of 
belonging at the clinic (Fig. 2). The value of individual contact 
and being treated with respect is therefore apparent. The chatter 
in the waiting room is itself proof of the fact that clinic visits 
are viewed as a social outing (Fig. 2). Eighty-one per cent of 
patients appreciated the opportunity of meeting other patients 
with similar problems and sharing their experiences. Almost all 
patients agreed that they enjoyed the comfort and quality of the 
facilities and that they trusted the institution and staff involved 
in the trials, an indication of the importance of the trial staff’s 
relationship with patients enrolled in trials. 
Clinical trials are often time consuming due to the length of 
the consultations and the time it takes to complete all protocol-
related tests. This time factor plays a major role in the patient 
recruitment process and needs to be discussed during the 
informed consent process. Only 7% of patients at this trial centre 
felt that they did not have the time required to participate in a 
clinical trial. 
One of the greatest benefits of participating in a clinical 
trial is the understanding patients gain of their disease and the 
management thereof. A substantial 98% of patients agreed that 
their involvement in the clinical research project was related to 
learning more about their disease (Fig. 3). The contribution to 
further the scientific understanding of their condition is an altru-
istic motivation expressed by 99% of the subjects. This motiva-
tion is shared by trial participants in developed countries who 
include contributing to science as one of the main motivations 
for wanting to participate in a clinical trial.4,5
It was intriguing that 78% of patients felt that not participat-
ing in a trial posed a serious threat to their health. This may 
indicate a level of patient vulnerability in state patients who do 
not receive adequate healthcare, and enrol in trials to safeguard 
their health. This is not a motivation found only in developing 
countries, however, as this sentiment was shared by the group 
of British diabetic patients who listed ‘reducing the threat of my 
disease’ as one of their strongest motivations for participating in 
a clinical trial.3 
The influence of other people and external loci on deciding 
whether to participate in a clinical trial was also investigated 
(Fig. 4). The influence of a doctor in the decision-making proc-
ess is often debated, especially in vulnerable subjects who are 
frequently uneducated and easily impressed (known as the ‘white-
coat syndrome’). It is reassuring to see that while 67% of patients 
were advised by their doctor to take part, 94% of subjects felt 
that they were not pressurised into the study by trial personnel. 
The influence of family and friends should not be underesti-
mated, as was discovered in this study. Almost half of all patients 
claimed that they were influenced by their family and friends to 
participate in a clinical trial. It is evident that the families of patients 
play an important role in patient recruitment in this country. 
The influence of money proved to be, in the patients’ opin-
ion, of minor importance (Fig. 4). Eighty per cent of patients 
disagreed that participation in clinical trials was an easy way 
to obtain money. Remuneration appeared to play a very small 
contributory role in patient recruitment. This is supported by the 
response given by patients enrolling in an HIV vaccine-efficacy 
trial, where only 14% listed financial reimbursement as a reason 
for enrolling in the trial.5
The potential limitations of a self-administered questionnaire 
should be taken into account when analysing the results of such 
a study. The authors did validate the questionnaire prior to imple-
mentation in order to minimise any possible misunderstanding or 
misinterpretation. 
Conclusion
This study presents, from a patient’s perspective, the reasons 
behind some South African patients enrolling in clinical trials. 
There are few, if any, such data currently available. Although 
there seem to be numerous factors that influence a patient’s 
decision to participate in a clinical trial, access to medical care 
and making a contribution to scientific knowledge appear to be 
two of the most common motivations. The role of remuneration, 
despite this being a comparatively poor and vulnerable popula-
tion, was relatively unimportant. 
These results not only provide an understanding of trial 
patients’ motivations, but also supply vital information to use 
in patient recruitment and retention. In addition, these results 
suggest that potentially vulnerable South African subjects are 
not being exploited by large foreign pharmaceuticals but rather 
that this is a mutually beneficial relationship. Every clinical 
trial needs to be conducted with the patient in mind if it is to be 
successful.6 These results offer an insight into the factors playing 
a role in patients’ decision making and therefore are invaluable 
to clinical researchers. 
The authors thank the clinical co-ordinators and administrative staff at 
TREAD Research for their assistance with data collection.
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letter to the Editor
implantable cardioverter defibrillators after myocardial 
infarction
dear sir
With reference to the interesting review of implantable cardio-
verter defibrillators (ICD) after myocardial infarction by Dr RJ 
Myerburg,1 we would like to discuss some aspects of the article.
As mentioned by the author, left ventricular ejection frac-
tion (LVEF) is the main criterion for making the decision to 
implant an ICD in patients with prior myocardial infarction 
(MI). However, the author defines the cut-off value for a strong 
indication (class I, level of evidence A) lower than (< 25%) that 
recommended by current ACC/AHA/HRS guidelines (< 30%),2 
despite using the same studies. The determination of LVEF 
lacks a widely accepted ‘gold standard’ and there is considerable 
variability between different test modalities and even between 
different operators with the same modality. This is an important 
drawback to the use of LVEF as a criterion for ICD implantation, 
especially when the value is borderline. 
Therefore, multiplying subgroups of patients according to 
their ejection fraction (EF) (≤ 25%, 26–30%, 31–35% and 
> 35%), as indicated in Table 2, will increase the risk of inaccu-
racy of this technique and the difficulty of patient management. 
In Table 2, the author stated that heart failure with an EF of 
31–35% is an uncertain indication for ICD, whereas it is a class 
IA indication in the above-mentioned guidelines for NYHA class 
II or III patients. 
The author also assumed that physicians are familiar with 
the current criteria for ICD use in primary prevention after MI. 
In our experience, physicians caring for patients with ischaemic 
disease are unsure of when to refer patients for ICD implanta-
tion. Quality of care would be improved if practice guidelines 
were standardised and simplified.
Concerning the role of ischaemia, the author pointed out the 
fact that ventricular tachycardia or ventricular fibrillation caused 
by transient ischaemia and the acute phase of myocardial infarc-
tion (24 to 48 hours after onset) are not predictive of recurrent 
events if recurrent ischaemia is preventable. However, the impact 
of incomplete revascularisation due to technical difficulties (for 
example inaccessible lesions) with residual ischaemia was not 
evaluated in clinical trials. Such patients could be at ongoing 
risk of fatal ventricular arrhythmia even with LVEF greater than 
35%. 
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